MEDiC
MEDiC Life Sciences is a biotechnology company that develops CRISPR-based cancer organoids for clinical trial research and drug development. The company has incorporated genome-scale CRISPR/Cas9 functional genomics tools into 3D cancer organoids based on specific cancer types, enabling systematic recapitulation of genetic mutations found in tumors. MEDiC proprietary tumor-immune co-culture system integrated with…
Funding snapshot
About
MEDiC Life Sciences is a biotechnology company that develops CRISPR-based cancer organoids for clinical trial research and drug development. The company has incorporated genome-scale CRISPR/Cas9 functional genomics tools into 3D cancer organoids based on specific cancer types, enabling systematic recapitulation of genetic mutations found in tumors. MEDiC proprietary tumor-immune co-culture system integrated with CRISPR technology allows researchers to precisely assess the functional contribution of cancer mutations for tumor growth, immune response, and drug response, identifying biomarkers, synthetic lethality, and resistant mutations for novel cancer drug development. The platform addresses the gap in current drug development systems that miss potential biomarkers and novel drug targets by combining the power of CRISPR functional genomics with the accuracy and translatability of patient tumor-like cancer models. Founded in 2019 and headquartered in San Carlos, California, MEDiC has raised $13 million in seed funding from investors including Hanmi Pharmaceuticals, LG Chem, Illumina, Top Harvest Capital, and Wing Venture Capital.
Business model
Genomics > Enabling Technologies > Technology Platforms > Genetic Engineering
Team background
College Wise > Stanford University
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.